Assistant Professor of Radiation Oncology
Radiation Oncology
2215 Fuller Rd
Ann Arbor, MI 48105
[email protected]
2215 Fuller Rd
Ann Arbor, MI 48105
Available to mentor
Alex Bryant, MD, MAS
Assistant Professor
-
Resident in Radiation OncologyUniversity of Michigan Medical School, Ann Arbor, 2023
-
Chief Resident in Radiation OncologyUniversity of Michigan Medical School, Ann Arbor, 2023
-
Transitional Medicine InternSanta Clara City Library, Santa Clara, 2019
-
M.D.University of California - San Diego School of Medicine, San Diego, 2018
-
M.A.S.University of California, San Diego, San Diego, 2017
-
B.S.Yale University, New Haven, 2012
-
Center MemberRogel Cancer Center
-
Center MemberInstitute for Healthcare Policy and Innovation
Dr. Bryant is interested in precision screening for lung and prostate cancer, cancer epidemiology, oncology data science in the Veterans Affairs system, natural language processing of clinical text, competing mortality prediction, and identification of heterogenous treatment effects in large clinical databases.
-
Elaimy AL, El-Derany MO, James J, Wang Z, Pearson AN, Holcomb EA, Huber AK, Gijón M, Bell HN, Sanghvi VR, Frankel TL, Su GL, Tapper EB, Tai AW, Ramnath N, Centonze CP, Dobrosotskaya I, Moeller JA, Bryant AK, Elliott DA, Choi E, Evans JR, Cuneo KC, Fitzgerald TJ, Wahl DR, Morgan MA, Chang DT, Wicha MS, Lawrence TS, Shah YM, Green MD. JCI Insight, 2024 Nov 8; 9 (21):Journal ArticleSLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma.
DOI:10.1172/jci.insight.184826 PMID: 39287988 -
Miller SR, Schipper M, Fritsche LG, Jiang R, Strohbehn G, Ötleş E, McMahon BH, Crivelli S, Zamora-Resendiz R, Ramnath N, Yoo S, Dai X, Sankar K, Edwards DM, Allen SG, Green MD, Bryant AK. Cancer Med, 2024 Nov; 13 (21): e70379Journal ArticlePan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System.
DOI:10.1002/cam4.70379 PMID: 39508134 -
Moncion A, Bryant AK, Cardenas CE, Dess KJ, Ditman MN, Mayo CS, Mierzwa ML, Paradis KC, Stanley DN, Covington EL. Pract Radiat Oncol, 2024 14 (6): e522 - e529.Journal ArticleQuantifying the Risk of Technology-Driven Health Disparities in Radiation Oncology.
DOI:10.1016/j.prro.2024.06.009 PMID: 38992491 -
Riviere P, Deshler LN, Morgan KM, Qiao EM, Bryant AK, Rose BS. J Urol, 2024 Nov; 212 (5): 709Journal ArticleReply by Authors.
DOI:10.1097/JU.0000000000004165 PMID: 39077981 -
Pflederer T, Miller SR, Jackson WC, Elliott DA, Green M, Dess RT, Bryant AK. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): e574Proceeding / Abstract / PosterUltra-Short-Course Hormone Therapy for Intermediate Risk Prostate Cancer Treated with Definitive Radiotherapy: Retrospective Analysis of a National Healthcare System
DOI:10.1016/j.ijrobp.2024.07.1268 -
Miller SR, Tucker R, Jackson WC, Caram ME, Tsao PA, Stensland KD, Elliott DA, Green M, Schipper M, Dess RT, Bryant AK. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): e561 - e562.Proceeding / Abstract / PosterUptake and Positivity Rates of PSMA PET Staging for Newly Diagnosed Prostate Cancer in a National Healthcare System
DOI:10.1016/j.ijrobp.2024.07.1244 -
Edwards DM, Pirzadeh M, Van T, Jiang R, Tate A, Schaefer G, James J, Bishop C, Wilson C, Nedzesky N, Alseri A, Leveque A, Malus A, Waljee A, Elliott DA, Deng J, Schwartz A, Schipper M, Bryant AK, Ramnath N, Green MD. Cancer, 2024 Sep 1; 130 (17): 2910 - 2917.Journal ArticleImpact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer.
DOI:10.1002/cncr.35340 PMID: 38853532 -
Bryant AK, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles KM, Rae JM, Tate A, Pearson AN, Jiang R, Fritsche L, Lawrence TS, Zou W, Schipper M, Ramnath N, Yoo S, Crivelli S, Green MD. Cancer Med, 2024 Jun; 13 (12): e7253Journal ArticleArtificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances.
DOI:10.1002/cam4.7253 PMID: 38899720
Health Lab
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
